Generics - Forest Laboratories, Pharmaceutical

Filter

Popular Filters

Lundbeck/Takeda's Brintellix has blockbuster potential

02-08-2013

Denmark CNS drug specialist Lundbeck (LUND: CO) and partner Japanese drug major Takeda Pharmaceutical's…

BrintellixedivoxetineEli LillyFetzimaForest LaboratoriesGenericsGlobalLundbeckMarkets & MarketingNeurologicalPharmaceuticalPierre FabreTakeda Pharmaceuticals

Forest agrees another license deal for Bystolic

22-07-2013

US drugmaker Forest Laboratories (NYSE:FRX) and Forest Laboratories Holdings have reached a settlement…

Amerigen PharmaceuticalsBystolicCardio-vascularForest LaboratoriesGenericsLicensingNorth AmericaPharmaceutical

Drugmakers to continue facing growing generic competition in 2013

17-02-2013

Last year saw the expiration of patents for several blockbuster drugs, leading to increasing generic…

AmarinFinancialForest LaboratoriesGenericsPatentsPharmaceutical

Insights on the US Alzheimer's disease market

03-12-2012

The treatment of Alzheimer's disease (AD) offers a compelling commercial opportunity for the pharmaceutical…

AriceptEisaiExelonForest LaboratoriesGenericsMarkets & MarketingNamendaNeurologicalNorth AmericaNovartisPfizerPharmaceutical

Forest Labs links with moksha8 for Viibryd in Latin America; Watson sells minority stake

24-10-2012

US drugmaker Forest Laboratories (NYSE: FRX) has entered into a broad strategic alliance with Brazil-based…

Forest LaboratoriesGenericsLicensingMergers & AcquisitionsMoksha8NeurologicalPharmaceuticalSouth AmericaViibrydWatson Pharmaceuticals

Forest Labs cuts FY 2013 earnings forecasts on Lexapro woes

12-06-2012

Following the expiration of US drugmaker Forest Laboratories' (NYSE: FRX) once best-selling anxiety drug…

FinancialForest LaboratoriesGenericsLevothroidLexaproPharmaceutical

Back to top